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Virotherapy of cancer using oncolytic adenoviruses has shown promise in both preclinical and clinical settings. One important challenge to
reach the full therapeutic potential of oncolytic adenoviruses is accomplishing efficient infection of cancer cells and avoiding uptake by normal
tissue through tropism modification. Towards this goal, we constructed and characterized an oncolytic adenovirus, carrying mutated capsid proteins
to abolish the promiscuous adenovirus native tropism and encoding a bispecific adapter molecule to target the virus to the epidermal growth factor
receptor (EGFR). The new virus displayed a highly selective targeting profile, with reduced infection of EGFR-negative cells and efficient killing of
EGFR-positive cancer cells including primary EGFR-positive osteosarcoma cells that are refractory to infection by conventional adenoviruses. Our
method to modify adenovirus tropism might thus be useful to design new oncolytic adenoviruses for more effective treatment of cancer.
© 2006 Elsevier Inc. All rights reserved.Keywords: Gene therapy; Oncolytic adenovirus; Targeting; Coxsackie and adenovirus receptor; Epidermal growth factor receptor; OsteosarcomaIntroduction
Conditionally replicating adenoviruses (CRAds) are being
explored for treatment of cancer. They kill cancer cells by
specifically replicating in and lysing these cells, allowing lateral
spread of progeny virus. The amplification of input dose and the
mechanism of cell kill are clearly different from conventional⁎ Corresponding author. Fax: +31 20 444 2126.
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doi:10.1016/j.virol.2006.11.011treatment, which make CRAds a promising, complementary
approach in anti-tumor therapy. So far, clinical trials using local,
loco-regional, or systemic application of CRAds have demon-
strated biological activity but only modest anti-cancer efficacy
(Kirn, 2001; Reid et al., 2002). The utility of CRAds is in part
hampered by the promiscuous tropism of the commonly used
adenovirus type 5 based vectors, which results in uptake by
normal tissues. This limits the amount of virus available for
infection of tumor cells and may cause toxic side effects, a
concern especially relevant for systemic treatment. Moreover,
several tumor cell types including glioblastoma, melanoma and
osteosarcoma were found to be refractory to adenovirus
transduction because of low expression of the high-affinity
Fig. 1. Schematic representation of the viruses used in this study. The parental
CRAd AdΔ24 carries a deletion of 24 base pairs in the E1 region to restrict
replication to cells with a defective Rb pathway and a deletion of the E3 region.
The CRAd AdΔ24-425S11 is identical to AdΔ24 except for an expression
cassette inserted in place of the E3 region encoding the bispecific single chain
antibody 425-S11 to allow infection via EGFR. The CRAd AdΔ24*F*-425S11
is identical to AdΔ24-425S11 except that it encodes a mutant penton base
protein with an RGD to RGE substitution that ablates the integrin binding site
and a fiber protein with a TAYT deletion that abrogates CAR binding.
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2001; Hemmi et al., 1998; Miller et al., 1998; Witlox et al.,
2002). Furthermore, primary ovarian and brain tumors showed a
large degree of heterogeneity in CAR expression between
different specimens but also within one tumor (Grill et al., 2001;
Zeimet et al., 2002). The relatively low and heterogeneous
expression of the native adenovirus receptor might compromise
cancer gene therapy with oncolytic adenoviruses. Indeed, it has
been found that the efficiency by which a CRAd is able to
destroy tumor cells in vitro and in vivo is critically dependent on
CAR expression status (Douglas et al., 2001). CRAd efficacy
can be improved by targeting the vector to tumor tissue
independently from CAR (Bernt et al., 2003; Suzuki et al.,
2001; Van Beusechem et al., 2003). Proper targeting of CRAds
to tumor cells should fulfill two requirements; i.e., the virus
should be engineered to transduce the cells of interest with high
efficiency and its natural tropism towards nontargeted tissues
should be abolished.
Several strategies have been employed to broaden the
tropism of Ad5-based gene transfer vectors (Mizuguchi and
Hayakawa, 2004) and some of these strategies have been
incorporated in CRAds to enhance oncolytic efficacy. The
approaches can be roughly divided in those that involve direct
genetic modification of the capsid proteins and those that rely
on conjugating adenovirus with adapter molecules. CRAds
carrying foreign peptides in the fiber exhibited an expanded
tropism leading to augmented oncolysis in vitro and in vivo
(Shinoura et al., 1999; Suzuki et al., 2001). Also CRAds
carrying chimeric fibers that were created by exchanging parts
of the Ad5 fiber protein with that of different adenovirus
serotypes displayed augmented infectivity on CAR-deficient
cancer cells (Bernt et al., 2003; Haviv et al., 2002). Although
these studies clearly demonstrate the benefits of targeting via
CAR independent pathways, the applicability of these targeting
approaches is not without limitations. Insertions in the fiber are
restricted by so far not fully understood structural demands for
retaining proper trimerisation of the fiber and pseudotyped
viruses are limited by the targeting repertoire of naturally
occurring adenovirus serotypes (Krasnykh et al., 2000). In
contrast, approaches that use a bispecific adapter molecule to
bind the virus to a cell-type specific protein are more flexible
(Dmitriev et al., 2000; Haisma et al., 2000; Nettelbeck et al.,
2001). The cell-binding component can be for example a single
chain monoclonal antibody (scFv). This antibody-based
approach combines excellent selectivity and affinity with
versatility. A disadvantage of this two-component approach is
that the targeting moiety is not an integral part of the adenovirus
capsid. Utility in the CRAd context requires that the gene
encoding the adapter protein is incorporated in the CRAd
genome to ensure that the targeting property is retained upon in
situ replication and spread through the tumor mass. Previously,
we confirmed utility of this concept. To that end, we developed
the CRAd AdΔ24-425S11 that encodes a bispecific single-
chain antibody (scFv) consisting of anti-epidermal growth
factor receptor (EGFR) scFv 425 and anti-adenovirus fiber knob
scFv S11 (Van Beusechem et al., 2003). This CRAd produced
425-S11 scFv during replication in cancer cells yieldingprogeny with enhanced infectivity and oncolysis properties on
EGFR-positive, CAR-deficient tumor cells. In addition to
infection via EGFR, AdΔ24-425S11 retained native infection
capacity via binding to CAR and integrins. To achieve strict
targeting, the native tropism of the CRAd should be abolished.
This is especially important for systemic delivery of CRAds
because the vast majority of intravenously injected adenovirus
is sequestered in the liver (Bernt et al., 2003; Einfeld et al.,
2001). Detargeting adenovirus from normal tissue upon
intravenous injection in mice and rats required ablation of
both CAR and αv integrin-binding sites (Einfeld et al., 2001;
Nicol et al., 2004). Therefore, we introduced mutations that
abolish CAR- and integrin-binding in the genome of AdΔ24-
425S11. This should produce a CRAd lacking CAR and αv
integrin-binding sites capable of producing EGFR-targeted
progeny upon replication in cancer cells. We show here that the
new CRAd AdΔ24P*F*-425S11 exhibited a strictly EGFR-
dependent targeting profile. In contrast to AdΔ24-425S11 with
intact native binding sites, the new virus showed reduced
replication and thus improved safety on EGFR-negative cells.
Similar to AdΔ24-425S11, it exhibited enhanced oncolytic
potency on CAR-negative, EGFR-positive cancer cell lines and
on primary osteosarcoma specimens. Additionally, we eval-
uated the targeting properties of AdΔ24P*F*-425S11 on
human liver tissue using a recently developed ex vivo liver
slice model.
Results
Construction and characterization of the CRAd
AdΔ24P*F*-425S11
Fig. 1 shows a schematic representation of the viruses used
in this study. All three CRAds carry the Δ24-deletion in the
E1A CR2 domain responsible for binding Rb protein (Fueyo et
al., 2000). AdΔ24-425S11 contains an expression cassette for
the EGFR-targeting bispecific antibody 425-S11 (Van Beuse-
chem et al., 2003). AdΔ24-425S11-infected cells secrete 425-
S11 adapter protein. Following oncolysis, released virus
progeny bind adapter protein, which confers targeted tropism.
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AdΔ24-425S11 by introducing two mutations that abolish
CAR- and integrin-binding sites in its fiber and penton genes,
respectively (Einfeld et al., 2001; Roelvink et al., 1999). To
allow propagation of this CRAd in the absence of native virus–
receptor interactions, we generated the 911-S11 cell line. This
E1-complementing cell line expresses an artificial receptor that
binds adenovirus fiber knob distinct from its CAR-binding site.
To compare the targeting properties of the three CRAds, we
selected a panel of 6 cancer cell lines differing in CAR- and
EGFR-expression. Fig. 2A shows flow cytometry analysis for
CAR and EGFR expression by these cells. Relative median
fluorescence (RMF) values were used to categorize cells as
negative or positive for expression (Fig. 2B). T24 cells did not
express detectable CAR, but did express EGFR. In contrast,
SW620 and MDA-MB-453 cells were positive for CAR and
negative for EGFR. The other three cell lines all expressed
EGFR and also expressed low (A431), intermediate (MDA-
MB-231) or high (A549) levels of CAR.
AdΔ24, AdΔ24-425S11 and AdΔ24P*F*-425S11 virus
stocks essentially lacking 425-S11 protein were prepared by
releasing virus from production cells in fresh culture medium,
followed by CsCl gradient banding. A549 (CAR+/EGFR+),
T24 (CAR−/EGFR+) and SW620 (CAR+/EGFR−) cells were
infected with these viruses and stained for expression of
adenoviral hexon 2 days after infection (Fig. 3). On the CAR-Fig. 2. CAR and EGFR expression of the cell lines used in this study. (A) Flow cytome
cells that were analyzed for CAR (dotted lines) and EGFR (bold grey lines) expressio
EGFR expression on the cell surface are given as the median fluorescence intens
fluorescence of second antibody-stained control cells (RMF).negative cell line T24, all three CRAds showed low infection
efficiencies, whereas AdΔ24 and AdΔ24-425S11 infected
CAR-positive A549 and SW620 cells with high efficiency. In
sharp contrast, the native tropism-ablated AdΔ24P*F*-425S11
exhibited low infection efficiencies on all three cell lines. These
findings thus demonstrated that the mutations introduced in the
penton and fiber genes of AdΔ24P*F*-425S11 effectively
reduced native infectivity. They also confirmed that the virus
particles were largely devoid of bispecific 425-S11 scFv. To
mimic in situ produced 425-S11-carrying virus progeny, we pre-
incubated virus with recombinant 425-S11 prior to inoculation
of the cells (Fig. 3). Precomplexation of the control viruses
AdΔ24 and AdΔ24-425S11 led to a minor increase in
transduction efficiency on CAR-positive A549 cells and a
clear increase on CAR-negative EGFR-positive T24 cells.
Precomplexation of AdΔ24P*F*-425S11 with 425-S11 protein
also increased infection of EGFR-positive A549 and T24 cells,
but most importantly, infection of SW620 cells that are negative
for EGFR remained low. The specificity of this retargeting was
further confirmed using soluble EGFR to block EGFR-
mediated entry. Incubating AdΔ24P*F-425S11 complexed
with 425-S11 with soluble EGFR negated infection of A549
and T24 cells. Together, these results strongly suggest that the
new EGFR-targeted CRAd AdΔ24P*F*-425S11 with ablated
native tropism, has a targeting phenotype strictly dependent on
the EGFR-targeting antibody and cellular EGFR-expression.try histograms of A431, A549, MDA-MB-231, MDA-MB-453, SW620 and T24
n. Second-antibody only controls are indicated by the black lines. (B) CAR and
ities of anti-CAR or anti-EGFR antibody-stained cells divided by the median
Fig. 3. Native tropism-ablated AdΔ24P*F*-425S11 complexed with recombinant 425-S11 scFv selectively infects EGFR-positive cells independent of CAR-status.
A549, T24 and SW620 cells with different expression of CAR and EGFR as indicated, were infected at 1000 VP/cell with AdΔ24, AdΔ24-425S11 or AdΔ24P*F*-
425S11. Prior to infection, purified virus was either untreated (−) or allowed to conjugate to recombinant scFv 425-S11 (+). Where indicated, soluble EGFR (sEGFR)
was added to the virus mixture. Two days after infection, cells were immunohistochemically stained for expression of hexon protein.
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EGFR-positive cancer cells
Next, we examined whether reduced native infectivity of
AdΔ24P*F*-425S11 virus translated into reduced cytotoxic
replication on CAR-positive, EGFR-negative cells. Monolayers
of cells varying in CAR and EGFR status were infected with
425-S11-precomplexed CRAds at various multiplicities of
infection (MOIs). Subsequently, CRAds were allowed to
replicate for 2 to 3 weeks, after which monolayer cytolysis
was examined by crystal violet staining (Fig. 4A). Cells
expressing CAR and EGFR could be killed by all three CRAds,
with AdΔ24-425S11 capable of infecting via both molecules
being generally most effective. Monolayers of CAR-positive,
EGFR-negative SW620 and MDA-MB-453 cell lines were
eradicated effectively following infection with AdΔ24 or
AdΔ24-425S11. In striking contrast, the monolayers of these
cells infected with AdΔ24P*F*-425S11 remained intact even atvery high MOI. This suggested that the mutations present in the
fiber and penton base of this virus effectively blocked its ability
to infect and kill CAR-positive EGFR-negative cells. Impor-
tantly, AdΔ24P*F*-425S11 exhibited clearly improved onco-
lytic potency compared to AdΔ24 on CAR-negative EGFR-
positive T24 cells. This showed that in situ production and
secretion of 425-S11 from the expression cassette present in
AdΔ24P*F*-425S11 restored its oncolytic potency on EGFR-
positive cells. To confirm these findings in an independent
manner, the infections were repeated three times, following
which cell viability was quantified by measuring WST-1
conversion. Fig. 4B shows a representative example of these
experiments, which confirmed the crystal violet CPE assay data.
Relative oncolytic potencies of the CRAds were determined on
the basis of TCID50 values. On the two EGFR-deficient cell
lines, AdΔ24P*F*-425S11 was 192- and 294-fold attenuated
compared to AdΔ24. In contrast, AdΔ24P*F*-425S11 was
160-fold more potent than AdΔ24 against CAR-deficient
Fig. 4. AdΔ24P*F*-425S11 exhibits selective oncolytic potency on EGFR-positive cells and improved safety on CAR-positive, EGFR-negative cells. (A) Human
cancer cell lines with different expression of CAR and EGFR as indicated, were infected with AdΔ24, AdΔ24-425S11 or AdΔ24P*F*-425S11 at the indicated
multiplicity of infection (MOI) or mock infected (M). Two to three weeks after infection, surviving cells were stained using crystal violet. Each cell line was tested at
least twice. Data shown are from representative experiments. (B) Cells were infected at indicated MOI with AdΔ24 (closed diamonds), AdΔ24-425S11 (closed
squares) or AdΔ24P*F*-425S11 (open triangles). Two to three weeks after infection, cell viability was measured using a WST-1 conversion assay. Values given are
percentages of uninfected control cultures. Data are the mean values±S.D. from a typical experiment performed in triplicate.
60 J.E. Carette et al. / Virology 361 (2007) 56–67EGFR-positive T24 cells. We could thus conclude that
AdΔ24P*F*-425S11 exhibited a stringent EGFR-dependent
oncolytic potency.
AdΔ24P*F*-425S11 kills primary CAR-deficient human
osteosarcoma cells
Similar to what has been reported for primary cells isolated
from tumors derived from other tissues, primary high-grade
osteosarcomas are often CAR-negative and EGFR-positive
(Graat et al., 2005; Witlox et al., 2002). We evaluated the utilityof AdΔ24P*F*-425S11 on short-term cultures of primary high-
grade osteosarcomas isolated from patient biopsies. FACS
analysis for CAR revealed that all samples were deficient for
CAR with relative median fluorescence values ranging from 1.0
to 1.2. FACS analysis for EGFR revealed low to moderate
expression ranging from 1.8 to 3.8 (Fig. 5). As a stringent test
for anti-cancer efficacy of administered oncolytic adenovirus,
primary osteosarcoma samples were infected with AdΔ24,
AdΔ24-425S11 or AdΔ24P*F*-425S11 without adding bispe-
cific scFv targeting molecules. Following culture for up to
27 days, during which the CRAds may replicate and produce
Fig. 5. AdΔ24P*F*-425S11 exhibits enhanced oncolytic potency on primary CAR-deficient human osteosarcoma specimens. Expression of CAR and EGFR on 10
primary osteosarcoma short-term cultures was measured by FACS analysis. The expression of CAR and EGFR is indicated by their relative median fluorescence value.
All samples were negative for CAR while EGFR expression was low to moderate. Cells were subjected to infection with AdΔ24, AdΔ24-425S11 or Ad24ΔP⁎F⁎-
425S11 at 100 VP/cell and cultured for 16 to 27 days. Cell viability was measured byWST-1 conversion assay and is given as percent viability compared to uninfected
control cultures. Data are means+S.D. of sextuplicate measurements. Compared to AdΔ24, the EGFR-targeted AdΔ24-425S11 exhibited significant enhancement of
oncolytic potency in all tested specimens (P<0.05). The native tropism-ablated AdΔ24P*F*-425S11 led to significantly enhanced oncolytic potency compared to
AdΔ24 in 7 out of 10 specimens tested (P<0.05), the exceptions being OS1a, OS6 and OS8.
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WST-1 and compared to the viability of uninfected controls
(Fig. 5). No or only a small decrease in viability was observed inFig. 6. Ablated native tropism of AdΔ24P*F*-425S11 reduces infection of human liv
with Krumdieck thin-slice tissue slicer. Slices were infected at 1×108 VP/slice with
either untreated (black bars) or allowed to complex with recombinant scFv 425-S11
infectious particles present in the slices was determined by limiting-dilution infection
of slices derived from three human livers. (B) Immunohistochemical staining of 4 μm
negative control underwent the same procedure without primary antibody incubatioprimary osteosarcoma cells that were infected with the parental
virus AdΔ24. In contrast, AdΔ24-425S11 efficiently killed
these cells leading to a significant decrease in viabilityer slices. (A) Fresh human liver samples were obtained and thin-slices were made
AdΔ24-425S11 or AdΔ24P*F*-425S11. Prior to infection, purified virus was
(white bars). Two days after infection, lysates were prepared and the number of
of 911-S11 cells. Data shown are the mean values+ S.D. of six to nine infections
sections of human liver using antibodies directed against EGFR or CAR. The
n. Sections were counterstained with hematoxylin.
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native tropism-ablated derivative AdΔ24P*F*-425S11 also
infected and killed these osteosarcoma samples. Although
AdΔ24P*F*-425S11 was somewhat less effective than AdΔ24-
425S11, it caused a significant decrease in viability compared to
parental AdΔ24 in 7 out of 10 specimens. Hence, EGFR-
targeting via 425-S11 scFv enhances oncolytic potency on
CAR-negative EGFR-positive primary cancer cells also in the
context of a native tropism ablated CRAd.
Infectivity of AdΔ24P*F*-425S11 on human liver slices
As adenovirus localizes largely to the liver upon systemic
administration, it is worthwhile to examine transduction of liver
tissue. Because the 425-S11 scFv molecule binds human EGFR
only, such a study should be done on human liver material.
Therefore, we employed a recently developed model using
precision-cut human liver slices, which can be maintained ex
vivo for a short period of time after preparation (Rots et al.,
2005). Freshly prepared human liver slices were infected with
AdΔ24-425S11 or AdΔ24P*F*-425S11. Two days after infec-
tion, lysates were prepared from the slices and the amount of
infectious virus particles in the slices was determined. As shown
in Fig. 6A, infection with native tropism-ablated AdΔ24P*F*-
425S11 CRAd resulted in 289-fold reduced recovery of virus
from the liver slices compared to AdΔ24-425S11. This
suggested that injected AdΔ24P*F*-425S11 would be con-
siderably less sequestered by the human liver than a CRAd
retaining native binding sites. Interestingly, however, when
AdΔ24P*F*-425S11 was complexed with bispecific scFv 425-
S11 prior to inoculation, virus output was elevated 71-fold to
levels only slightly lower than observed with AdΔ24-425S11.
To investigate if this could be explained by liver cells expressing
EGFR, we performed immunohistochemical staining on human
liver slices using antibodies recognizing CAR and EGFR (Fig.
6B). Positive staining with both antibodies was observed, which
is in line with previous studies that reported CAR and EGFR
expression in human liver tissue (Reeves et al., 1994; Tomko et
al., 1997). Hence, while systemically injected AdΔ24P*F*-
425S11 is expected to exhibit strongly reduced liver tropism, its
in vivo produced 425-S11-carrying progeny is likely to be
sequestered by the liver via binding to EGFR.
Discussion
Proper targeting of oncolytic viruses to tumor cells requires
redirecting the virus to a tumor-specific antigen while
abolishing its native tropism. We have shown previously that
a CRAd expressing an EGFR-targeting bispecific adapter
molecule (425-S11) exhibited enhanced oncolytic potency on
CAR-deficient tumor cells in vitro and in vivo (Geoerger et al.,
2005; Van Beusechem et al., 2003). This infectivity-enhanced
virus retained ability to enter cells via CAR, thus potentially
limiting its utility due to its sequestration in normal tissue. Other
previously reported CRAds with enhanced oncolytic potency
on CAR-negative tumor cells include CRAds containing a
cyclic RGD peptide insertion in the fiber HI loop, a stretch oflysine residues added to the carboxy-terminus of the fiber
protein and Ad5/Ad3 or Ad5/Ad35 fiber chimeras (Bernt et al.,
2003; Rivera et al., 2004; Shinoura et al., 1999; Suzuki et al.,
2001). It is important to note that in most of these infectivity-
enhanced CRAds the tropism of the virus is expanded rather
than restricted to tumor cells. In fact, transduction of liver cells
and hepatotoxicity was significantly higher with replicating
adenoviruses containing the Ad5/Ad3 chimeric fiber compared
to the parental virus with wild-type Ad5 fibers (Rein et al.,
2005).
In this study, we describe a next generation targeted CRAd
that carries mutations in its fiber and penton genes to ablate
CAR- and integrin-dependent entry and expresses a bispecific
targeting-antibody. We predicted that this type of virus should
exhibit reduced native tropism, while its bispecific antibody-
carrying progeny would have targeted tropism. As prototype,
we made an EGFR-targeted variant expressing the 425-S11
adapter molecule. To the best of our knowledge, this CRAd is
the first oncolytic virus with abolished native tropism. We
evaluated infection and replication properties of this virus on
cancer cell lines, primary osteosarcoma cells and normal liver
cells. The new CRAd exhibited a clearly reduced transduction
efficiency on CAR-positive cells, which is in line with previous
findings with replication-deficient vectors carrying similar
native tropism ablating mutations (Einfeld et al., 2001;
Nettelbeck et al., 2004; Van Beusechem et al., 2002a).
Compared to non-ablated viruses, safety of the novel CRAd
on CAR-positive, EGFR-negative cells was considerably
improved rendering the virus unable to infect and kill these
cells even at high MOI. Importantly, retargeting the native
tropism-ablated virus towards EGFR-positive cells using in situ
produced bispecific 425-S11 antibody resulted in much higher
(on CAR-negative cells) or comparable (on CAR-positive cells)
oncolytic potencies compared to non-targeted parental AdΔ24
virus. Experiments using cells with different CAR and EGFR
expression profiles and competition with soluble EGFR showed
that infection by AdΔ24P*F*-425S11 was strictly EGFR-
mediated. Hence, we showed that a CRAd with native tropism
ablation that expresses its own targeting adapter displays a
highly selective targeting profile.
The targeted replication of AdΔ24P*F*-425S11 was
verified on freshly isolated, primary osteosarcoma cells which
may represent clinically more relevant substrates compared to
established cell lines. It has been reported previously that the
CAR expression on cells derived from primary high-grade
tumors is generally low. Indeed, all 10 osteosarcoma specimens
tested showed undetectable CAR expression. To mimic clinical
application of the new type of targeted CRAd, we subjected
these cells to virus without adding recombinant adapter
antibody. In this setting, the benefit of EGFR-targeting relies
entirely on adapter protein production during oncolytic
replication. In 7 out of 10 samples, the native tropism-ablated,
EGFR targeted virus was significantly more effective in killing
primary osteosarcoma cells through multiple rounds of infection
and replication compared to the parental CRAd. Interestingly,
on several specimens AdΔ24-425S11 was more oncolytic than
AdΔ24P*F*425S11. Although we cannot formally exclude that
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virus titers, we favor the explanation that AdΔ24-425S11 was
more effective because the primary OS cells expressed αv
integrins. Also in the absence of CAR, these molecules may
serve as entry receptors for AdΔ24-425S11 with intact penton
base, but not for AdΔ24P*F*-425S11 with mutated penton
base. In fact, we have previously shown that the infectivity-
enhanced CRAd Ad5-Δ24RGD, which targets αv integrins,
efficiently infects primary OS cells (Witlox et al., 2004). For
this reason, a somewhat higher oncolytic potency of AdΔ24-
425S11 than AdΔ24P*F*-425S11 was not unexpected.
It has been reported previously that bispecific adapter
molecules, including S11-based proteins, that bind to the
adenovirus fiber knob can block CAR-dependent entry (Haisma
et al., 1999; Kashentseva et al., 2002; Watkins et al., 1997). If
this block were always efficient, there would be no need to
further ablate CAR-binding by introduction of mutations in the
fiber. In our experiments, addition or stable expression of 425-
S11 did not abolish oncolytic replication of CRAds on CAR-
positive, EGFR-negative cell lines. This suggests that bispecific
antibody concentrations required for neutralization were not
reached. Presumably, binding of 425-S11 to only few fiber
proteins per virus particle is already sufficient to mediate
adenovirus entry via EGFR, whereas neutralization of CAR-
mediated adenoviral transduction requires excess antibody to
cover all fiber proteins. These considerations are especially
relevant for in vivo applications where virus-adapter binding
cannot be controlled and antibody adapters might dissociate
over time. As shown herein, genetic ablation of CAR- and
integrin-binding causes a strong reduction in native infection
and oncolysis, obviating the need to control neutralization by
the bispecific antibody.
The use of bispecific adapter molecules based on mono-
clonal antibodies allows flexibility in the choice of tumor
antigen. By way of example, we chose the 425 monoclonal
antibody that is directed against EGFR. The validity of EGFR as
specific target is supported by the clinical development of
EGFR inhibitors of which the human-mouse chimeric version
of anti-EGFR monoclonal antibody C225 has been evaluated
through phase III trials (Herbst and Shin, 2002) and monoclonal
antibody 425 is being evaluated in phase I and II trials.
Although EGFR is frequently overexpressed in tumor cells, also
normal cells express EGFR including liver and skin (Herbst and
Shin, 2002; Reeves et al., 1994). Indeed, while the native
tropism-ablated virus AdΔ24P*F*-425S11 showed substantial
detargeting in the human liver slice model, complexation with
425-S11 largely restored infection of liver cells. It is likely that
this was caused by EGFR expression in the liver slices, which
we detected using immunohistochemistry. This finding dis-
courages systemic delivery of oncolytic viruses carrying EGFR-
binding ligands. Our targeting approach, where the EGFR-
targeting moiety is provided only upon oncolytic virus
replication, might perhaps circumvent this obstacle. Alterna-
tively, EGFR-targeting should primarily be considered for local
and loco-regional virotherapy approaches. Various such strate-
gies are clinically relevant and currently being evaluated. In
particular, malignant brain tumors are often CAR−/EGFR+,while normal brain tissue is CAR+/EGFR− (Grill et al., 2001;
Miller et al., 1998). A truly EGFR-targeted CRAd could be very
useful in this context. Moreover, the flexibility of the antibody-
based approach readily allows targeting to different antigens
specific for various types of cancer. Since we found that
ablation of native tropism decreased liver cell infection
considerably, our targeting concept might prove most useful if
targeting molecules are employed that are not expressed on liver
cells. Such specific targets have been described. A good
example is carbonic anhydrase IX or G250, which is
specifically expressed on renal cell carcinomas (RCC) and in
hypoxic tumor areas. Successful retargeting of a non-replicating
adenovirus vector towards RCC using a bispecific adapter mole-
cule directed to G250 was already reported (Jongmans et al.,
2003).
Oncolytic adenoviruses owe their tumor-selectivity to
specific mutations introduced in their genome. The AdΔ24
CRAd that we used as backbone to construct the targeted CRAd
contains a deletion in the pRb-binding CR2 region of the
adenoviral E1A protein that confers selective replication in cells
with abnormalities in cell-cycle checkpoints regulated by pRb
(Fueyo et al., 2000). Because pRb malfunction is shared by
many tumors, the replication efficacy and oncolytic potency of
AdΔ24 type CRAds could be demonstrated on a broad range of
cancer cells (Balague et al., 2001; Fueyo et al., 2000; Geoerger
et al., 2004, 2005; Johnson et al., 2002; Suzuki et al., 2001; Van
Beusechem et al., 2002b). In the present study, we aimed to
enhance tumor-selective replication of the potent CRAd AdΔ24
by tumor-selective infection via EGFR and we demonstrate that
this indeed abolished replication and cell kill on CAR-positive
EGFR-negative cells. Because neither transductional targeting
nor selective replication is perfect by itself, combining these
approaches may achieve a higher degree of tumor-specificity.
The targeting approach presented herein might therefore
contribute to the development of safer and more potent
CRAds for cancer virotherapy.
Materials and methods
Cell lines and primary osteosarcoma specimens
A431 squamous skin carcinoma cells, A549 lung carcinoma
cells and MDA-MB-231 and MDA-MB-453 breast carcinoma
cells were all obtained from the ATCC (Manassas, VA, USA).
T24 bladder cancer cells and SW620 colorectal carcinoma cells
were kindly provided by Dr H.G. van der Poel (Department of
Urology, NKI, Amsterdam, Netherlands) and M.L. Janmaat
(Department of Medical Oncology, VU University Medical
Center, Amsterdam, The Netherlands), respectively. Adeno-
virus E1-complementing 911 cells were obtained from
IntroGene, Leiden, The Netherlands.
911-S11 cells were derived from 911 cells by transfecting
911 cells with the plasmid pDisplay-S11. pDisplay-S11 was
made by releasing the single chain anti-fiber antibody S11
encoding fragment from pSTCF-S11 (Haisma et al., 2000)
using SfiI and SalI and inserting it into pDisplay (Invitrogen,
Carlsbad, CA) digested with the same restriction enzymes.
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at a concentration of 500 μg/ml and a clonal cell population was
obtained by limiting dilution. Expression of the S11 scFv at the
surface of the cells was verified using immunocytochemistry.
Infection of 911-S11 cells via interaction of adenovirus fiber
with S11 allows functional titer assessment of CAR-ablated
viruses.
Fresh tumor material from patients suspected of having a
high-grade OS was processed directly after open biopsy surgery
as described earlier (Witlox et al., 2002). Cells were used for
experiments at passage 0–10. Confirmation of OS tumor cell
morphology of all short-term cultures was performed by
histopathology.
MDA-MB-453 cells were maintained in Leibovitz's L-15
medium (ATCC) supplemented with 10% FCS, 50 IU/ml
penicillin, and 50 μg/ml streptomycin (Life Technologies,
Paisley, United Kingdom). All other cells were maintained in
DMEM:Ham's F-12 supplemented with 10% FCS, 50 IU/ml
penicillin, and 50 μg/ml streptomycin (Life Technologies).
Adenovirus plasmid construction
To ablate CAR-binding, the plasmid pBHG11 (Bett et al.,
1994; Microbix Biosystems, Toronto, Canada) was modified to
contain the four amino acid deletion T489AYT492 in the FG loop
of the fiber. This deletion has been shown to ablate binding to
CAR (Roelvink et al., 1999) and will be referred to as F*. To
facilitate cloning, subclones of pBHG11 were made by
digestion of pBHG11 with XbaI and SpeI and religation to
form pBHG11ΔXbaΔSpe and digestion with AscI and religa-
tion to form pBHG11ΔAsc. Site-directed mutagenesis was
performed using overlap extension PCR (Ho et al., 1989). For
this, two separate PCR reactions were performed with plasmid
pBHG11 as template using either primers 5′-GGCGGACGGC-
TACGACTG-3′ and 5′-CATAAATCCAACAGCGTTGCCTT-
CAGTAAGGTCTCC-3′ or 5′-GGAGACCTTACTGAAGGCA-
ACGCTGTTGGATTTATG-3′ and 5′-CGGGAGGGTGCTA-
TTTTGCC-3′. Subsequently, the PCR products were combined
and used as template for a PCR reaction using primers 5′-
CGGGAGGGTGCTATTTTGCC-3′ and 5′-GGCGGACGGC-
TACGACTG-3′. The resulting PCR product that contains the
mutated fiber was digested with PacI and AvrII and ligated in
pBHG11ΔXbaΔSpe digested with the same enzymes. Subse-
quently, the ClaI/PacI fragment was released and introduced in
full-length pBHG11 to generate pBHG11F*. To abrogate
integrin-binding, the penton motif R340GD342 was changed into
the non-binding sequence R340GE342 (Obara et al., 1988). This
mutation will be referred to as P*. Site-directed mutagenesis was
performed using the primers 5′-GCCATCCGCGGCGAGA-
CCTTTGCCACAC-3′, 5′-TCACTGACGGTGGTGATGG-3′, 5′-
GGCAGAAGATCCCCTCGTTG-3′ and 5′-GTGTGGCAAAGG-
TCTCGCCGCGGATGGC-3′ with the pBHG11 plasmid as
template. The resulting PCR product containing the desired
mutation in the RGD motif was digested with PmeI and AscI and
introduced in pBHG11ΔAsc. Subsequently, the original AscI
fragment was reintroduced by ligation to form full-length
pBHG11P*. To construct pBHG11 containing both mutations,the ClaI/PacI fragment of pBHG11F* was introduced in
pBHG11P* digested with the same enzymes. This construct
was named pBHG11P*F*.
To construct pBHG11P*F*-425S11-R, the 4.1 kb PacI
fragment from pABS.4-425S11 (Van Beusechem et al., 2003)
carrying the CMV-425S11 cassette and kanamycin resistance
gene was inserted into pBHG11P*F*. A clone with an insert in
the orientation that places the CMV-425S11 cassette on the
adenovirus R-strand was isolated and the kanamycin resistance
gene was removed by digestion with SwaI followed by self-
ligation, yielding pBHG11P*F*-425S11-R.
Recombinant adenoviruses
The CRAds AdΔ24 and AdΔ24-425S11 were described
before (Van Beusechem et al., 2002b, 2003). The native
tropism-ablated EGFR-targeted CRAd AdΔ24P*F*-425S11
was made by homologous recombination in 911 cells between
pXC1-Δ24 (a generous gift of Dr Ramon Alemany, Gene
Therapy Center, UAB, AL, USA) and pBHG11P*F*-425S11-
R. AdΔ24, Ad24-425S11 and AdΔ24PF-425S11 carry the
same 24 bp E1A deletion in the pRb-binding CR2 domain in
E1A (Fueyo et al., 2000) and have identical deleted E3 regions
(Ad5 nt 27865–30995). They only differ in the CMV-425S11
cassette insertion present in Ad24-425S11 and AdΔ24PF-
425S11. Additionally, AdΔ24PF-425S11 contains the four
amino acid deletion T489AYT492 in the FG loop of the fiber and
the R340GD342 to R340GE342 substitution in the penton base that
abolish interaction of the virus with CAR and integrins,
respectively (Obara et al., 1988; Roelvink et al., 1999). Viruses
were propagated on A549 cells and released from cells
experiencing cytopathic effect by multiple freeze–thaw cycles
in fresh culture medium. This yields particles that are essentially
free from bispecific adapter protein. Purified virus stocks were
prepared by two successive bandings on CsCl gradients. Viruses
were stored at −80 °C in storage buffer (10 mM HEPES (pH
7.4), 150 mM NaCl, 1 mMMgCl2, 10% glycerol) until use. The
E1Δ24, P* and F* mutations and CMV-425S11 insertion were
confirmed by PCR on the final products. Physical viral particle
(VP) titers were determined by measurement of optical density
at 260 nm. Functional titers in plaque forming units (PFU) were
determined by limiting-dilution titration according to standard
techniques on 911 cells and on 911-S11 cells. The VP/PFU
ratios determined on 911 and 911-S11 were respectively 48 and
49 for AdΔ24, 9 and 13 for AdΔ24-425S11, and 2450 and 121
for AdΔ24PF-425S11. Since functional titers of viruses with
different tropism cannot be directly compared, all infections
were normalized by VP titers.
FACS analysis
CAR and EGFR expression levels on cell lines were
analyzed after incubating cells with RmcB anti-CAR MoAb
(Hsu et al., 1988) or 425 anti-EGFR MoAb (culture supernatant
from the 425 hybridoma cell line; ATCC), respectively,
followed by RbaMIgG-FITC (DAKO, Glostrup, Denmark).
Negative controls were incubated with second antibody only.
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Erembodegem-Aalst, Belgium), using CellQuest software
(Beckton-Dickinson). Relative median fluorescence (RMF)
signal intensity is defined as the ratio of the median
fluorescence signal intensity of anti-CAR MoAb or anti-
EGFR MoAb stained cells divided by that of the negative
control stained cells.
Assessment of CRAd transduction efficiency by immunohisto-
chemistry for adenoviral hexon protein expression
Cancer cells were seeded 1×104 per well in 96-well plates.
Where indicated, virus was pre-complexed 30 min at room
temperature with undiluted recombinant bispecific scFv 425-
S11 and/or soluble EGFR before inoculating the cells. Soluble
EGFR secreted by A431 cells (Weber et al., 1984), was isolated
from culture medium by centrifugation over an Amicon ultra-15
centrifugal filter device (Millipore, Carrigtwohill, Ireland). The
filtrate (without soluble EGFR) was used as negative control.
Cells were inoculated at 1000 VP/cell with AdΔ24, Ad24-
425S11 or AdΔ24P*F*-425S11 for 1 h at 37 °C, after which
virus-containing medium was replaced with fresh medium. Two
days after infection, cells were fixed with methanol and
immunohistochemically stained using the anti-hexon antibody
and other reagents provided in the Adeno-X rapid titer kit (BD
Bioscience, Clontech, Palo Alto, CA) according to the
manufacturer's protocol. Photos were taken using a 10×
objective.
Assessment of CRAd oncolytic potency by crystal violet CPE
assay and WST-1 cell viability assay
Cancer cells were seeded 5×104 per well in 24-well plates
for crystal violet assay or 5×103 per well in 96-well plates for
WST-1 assay. Before infection, virus was pre-complexed
30 min at room temperature with recombinant bispecific scFv
425-S11. Subsequently, cells were subjected to infection with
AdΔ24, Ad24-425S11 or AdΔ24P*F*-425S11 at a range of
MOIs for 1 h at 37 °C, after which virus-containing medium
was replaced with fresh medium. Cells were cultured for 2–
3 weeks with 50% medium refreshment every 4–5 days. For
crystal violet staining, the culture medium was then removed
and adherent cells were fixed for 15 min at room temperature
with 4% formaldehyde in PBS, and subsequently stained using
1% crystal violet dye in 70% ethanol for 30 min at room
temperature. After several washes with water, the culture plates
were air-dried and scanned on a Bio-Rad GS-690 imaging
densitometer. For the colorimetric WST-1 cell viability assay
(Roche Diagnostics, Mannheim, Germany), the culture medium
was replaced by 100 μl of 10% WST-1 in culture medium.
Depending on the cell type, the formation of the formazan dye
was allowed to proceed for 30–60 min at 37 °C after which the
A450 was measured on a Bio-Rad (Hercules, CA, USA) model
550 microplate reader. WST-1 conversion was expressed
relative to the conversion by uninfected control cells, after
subtraction of background values of WST-1 incubated in the
absence of cells. The 50% tissue culture inhibiting dose(TCID50; i.e., the MOI causing 50% reduction in WST-1
conversion) was determined using GraphPad Prism4 software.
Relative oncolytic potencies of AdΔ24P*F*-425S11 compared
to AdΔ24 on different cell lines were estimated by calculating
the average ratios of the TCID50 of AdΔ24 over that of
AdΔ24P*F*-425S11 from three independent experiments.
Replication and cytotoxicity of CRAds on primary
osteosarcoma specimens
Primary, short-term osteosarcoma cell cultures were seeded
5×103 cells per well to prepare subconfluent monolayers in 96-
well plates. The next day, the cells were infected at 100 VP/cell
with AdΔ24, Ad24-425S11 or AdΔ24P*F*-425S11 for 1 h at
37 °C,without adding bispecific scFv targeting molecules.
Subsequently, cells were cultured at 37 °C for 16–27 days
before analysis of cell survival byWST-1 conversion assay. Cell
survival was assessed using WST-1 as described by the
manufacturer (Sigma, St. Louis, MO). Survival is expressed
as a percentage of control uninfected cells. Statistical
significance of enhanced oncolysis by Ad24-425S11 and
AdΔ24P*F*-425S11 compared to AdΔ24 was tested by two-
tailed Students t-test.
Recovery of infectious viral particles from human liver slices
Human liver samples were obtained from the Department of
Surgery, Division of Hepatobiliary Surgery and Liver Trans-
plantation of the University Hospital Groningen after obtaining
approval of the local medical ethical committee and informed
consent. Samples were stored in University of Wisconsin
organ preservation solution (UW, Du Pont Critical Care,
Waukegan, IL) at 4 °C until slicing. Slices were prepared as
described previously (Olinga et al., 1998). In short, cores of
8 mm were drilled from the tissues, which subsequently were
sliced using a Krumdieck slicer (Alabama R&D, Munfort, AL)
for optimal and reproducible preparation of liver slices. The
thickness of the slices was adjusted to 200–250 μm (10–14 mg).
The slicing procedure itself was performed in ice-cold
physiological Krebs buffer. Slices were washed and pre-
incubated at 37 °C for 1 h in Williams' Medium E (WME)
supplemented with D-glucose (25 mM) and gentamycin (50 μg/
ml), saturated with 95% O2/5% CO2 before experiments were
started. Slices were infected by adding virus to 3.2 ml of fresh
oxygenated WME in 6-well plates. Where indicated, virus was
pre-complexed 30 min at room temperature with recombinant
bispecific scFv 425-S11 before inoculation. Subsequently, cells
were inoculated with AdΔ24, Ad24-425S11 or AdΔ24P*F*-
425S11 at 1×108 VP/slice for 2 h at 37 °C after which infection
medium was replaced with fresh medium. Slices were further
incubated in 95%O2/5%CO2 for 48 h at 37 °C under continuous
shaking. Slices were harvested 2 days after infection and lysates
were prepared in reporter lysis buffer (Promega, Madison, WI,
USA). The number of infectious particles present in the lysates
was determined using a limiting-dilution titration assay on 911-
S11 cells using the Adeno-X rapid titer kit (Clontech) according
to the manufacturer's protocol.
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Human liver material that remained after preparation of the
slices used for infection was frozen and sectioned at 4-μm-thick
for immunohistochemical staining for EGFR and CAR expres-
sion. Frozen sections were fixed in acetone and incubated with
the primary antibody against CAR (RmcB 1:100) or EGFR
(clone EGFR.113, Novacastra, Newcastle upon Tyne, UK) at
room temperature for 1 h. Subsequently, the sections were
stained using the Envision, Peroxidase/DAB detection kit
(DAKO) according to manufacturer's protocol. The sections
were counterstained with hematoxylin, dehydrated and cover
slipped. Tissue from normal skin was used as a positive control
for EGFR staining. As a negative control, the primary antibody
was replaced by PBS. Photos were taken using a 20× objective.
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